Average Insider

Where insiders trade, we follow

$AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Brian Goff
CEO
486
Employees
$37.00
Current Price
$1.61B
Market Cap
52W Low$22.24
Current$37.0062.1% above low, 37.9% below high
52W High$46.00

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells12$74,642.171,989
2 weeksBuys00--All Sells
Sells12$74,642.171,989
1 monthBuys00--All Sells
Sells12$74,642.171,989
2 monthsBuys00--All Sells
Sells12$74,642.171,989
3 monthsBuys00--All Sells
Sells13$989,042.1731,989
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Oct 21, 2026
Gheuens Sarah
Chief Medical Officer
Sale1,489$37.53$55,882.17View Details
Oct 22, 2026
Gheuens Sarah
Chief Medical Officer
Sale500$37.52$18,760.00View Details
Aug 4, 2026
Gheuens Sarah
Chief Medical Officer
Sale30,000$30.48$914,400.00View Details
40 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Oct 29, 2026
EPS
Estimated-$1.24
ActualN/A
Revenue
Estimated$53.36M
ActualN/A
Nov 5, 2026
EPS
Estimated-$1.25
ActualN/A
Revenue
Estimated$51.55M
ActualN/A

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.10.12